TX-BLUE-YONDER
1.8.2024 17:13:29 CEST | Business Wire | Press release
Blue Yonder, the leader in digital supply chain transformations, today announced the closing of its acquisition of One Network Enterprises (One Network) at an enterprise value of approximately $839 million. The acquisition gives Blue Yonder customers the ability to collaborate and share data – from inventory levels to raw and finished goods materials movement – in real time across all trading partners up and down the supply chain.
With increasing volatility and continuous disruptions, retailers, manufacturers and logistics service providers (LSPs) need to achieve multi-enterprise transparency with trading partners, unify plans and actions, and conduct business in real time in order to enable more accurate cross-functional decision-making and eliminate the time gap between order planning and fulfillment. It’s no longer sufficient for companies to rely on periodic updates about their inventory, capacity, and resources; true business agility requires real-time information across an entire network.
With the addition of One Network’s commercial technology, Blue Yonder can now offer customers a multi-enterprise, multi-tier network ecosystem; artificial intelligence (AI)-powered supply chain assistants to identify, monitor, analyze, and resolve problems; and a simplified process to onboard and work with trading partners. Real-time inventory and capacity views help customers match supply and demand, detect and resolve problems, and orchestrate resources across their network of trading partners. One Network will continue to independently service and provide tailored technology solutions to its government customers.
“One Network’s industry-leading commercial technology will seamlessly be integrated into the Blue Yonder Platform. Their supply chain network and intelligent control tower deliver superpowered insights to businesses looking to fortify their supply chains,” said Duncan Angove, CEO, Blue Yonder. “Our customers can boost visibility, agility and speed thanks to a single source of truth provided by the Blue Yonder Platform and the digital network, all enhanced by our AI assistants, solvers and predictions. This allows customers to see issues both downstream and upstream in real time, so they can avoid disruptions and make better decisions. From One Network’s capabilities to its forward-looking mission, the company perfectly embodies Blue Yonder’s vision to transform the supply chain.”
With this acquisition, Blue Yonder customers will be able to address volatility and disruptions in the market, plan with greater accuracy, meet rising customer expectations, and simplify complexity within their supply chains. Blue Yonder customers will have access to the following benefits:
- Navigating increasing uncertainty and volatility with real-time visibility across multiple tiers to anticipate risks, assess scenarios, and instantly redirect resources where needed most to deliver the greatest impacts to their business and sustainability goals.
- Optimizing of resources, from capacity and inventory to workforce and carriers to better serve their business customers, capitalize on new market opportunities, and accelerate revenue growth.
- Collaborating and orchestrating of their supply chain in real-time across a global network of 150,000 (and counting) trading partners using a shared view and dataset that ensures planning objectives flow into execution and vice versa to optimize critical KPIs.
“Blue Yonder is building the supply chain of the future,” said Angove. “To succeed in today’s business environment, planning and logistics teams need to make decisions faster. They need to collaborate with more partners. They need faster responsiveness to disruptions. One Network’s multi-tier and multi-enterprise network has a large role to play here, and we’re proud to join forces with them to make a lasting difference.”
This acquisition also catalyzed Blue Yonder’s expanded presence in Dallas, where it has been hiring extensively to support its momentum. Blue Yonder is now designating Dallas as its Global Innovation Center. In May during its annual customer conference, ICON, Blue Yonder announced a new AI Innovation Studio in Dallas where the company is hosting design-led AI Agent workshops with customers. Blue Yonder also plans to add a state-of-the-art Customer Experience Center in Dallas where the company will showcase its latest innovations that are transforming complex global supply chains.
One Network is the third company Blue Yonder has acquired since Q4 2023, following Doddle in November 2023 and flexis AG in February. These deals mark approximately $1 billion in M&A investments and are emblematic of Blue Yonder’s intent to transform the global supply chain.
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your PotentialTM www.blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731317929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
